Phase 4 N=261 Varenicline for Nicotine Vaping Cessation in Adolescents
Vaping · Nicotine Dependence
Primary: Continuous 4-week Nicotine Vaping Abstinence at End of Treatment (Weeks 9-12) — 45; 12; 5 Participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=8 Vaping THC From Electronic Cigarettes
Marijuana Dependence
Primary: Mean Delivered and Retained Doses — 0.016; 0.018; 0.026 grams (g)
N/A N=80 Low Nicotine Cigarettes Plus Electronic Cigarettes
Tobacco Dependence
Primary: Urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) — 505.6; 459.1; 373.3; 180.5 pg/mg creatinine — p=0.017
N/A N=15 Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study
Nicotine Dependence
Primary: Maximum Concentration of Nicotine in Plasma (Cmax) — 5.7; 11.8; 6.7; 8.1 ng/mL
N/A N=88 Evaluating E-Cigarette Nicotine Form, Concentration, and Flavors Among Youth
E-cigarette Use
Primary: Plasma Nicotine Concentration — 0.78; 1.08; 0.89; 1.16 ng/ml
N/A N=12 A Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product
Healthy Volunteers
Primary: Nicotine Plasma Concentration — 3.6; 2.5; 2.5; 21.2 ng/ml
Phase 2 N=40 Varenicline for Treatment of E-cigarette Dependence
Smoking Cessation
Primary: Number of Participants Abstinent From Vaping at Week 8 — 9; 6 Participants
N/A N=71 Vaper to Vaper: A Multimodal Mobile Peer Driven Intervention to Support Adolescents in Quitting Vaping
E-cigarette Use · Vaping
Primary: Participant Recruitment and Retention — 37; 31 Participants
N/A N=64 Cigarette and E-cigarette Nicotine Content in an Electronic Tobacco Marketplace (ETM)
Tobacco Use
Primary: Number of Cigarettes Purchased — 154.7; 119.2 average number of cigarettes
N/A N=38 Clinical Pharmacology of Electronic Cigarettes
Nicotine Dependence
Primary: Standardized Session: Mean CMax — 6.1; 20.2 ng/mL
N/A N=33 Assessing Electronic Cigarette Nicotine Flux
Electronic Cigarette Use
Primary: Plasma Nicotine Concentration — 2.00; 1.92; 1.64; 1.62 mg/ml
N/A N=27 Effects of Electronic Cigarettes on Nicotine Concentrations
Health Behavior
Primary: Effects E-cig Use on Venous Nicotine Concentrations Before and 5 Minutes After Use — 4.30; 4.11; 8.66; 8.77 ng/ml
N/A N=106 Goal2QuitVaping for Nicotine Vaping Cessation Among Adolescents
Depressive Symptoms · Depression · Adolescent Behavior
Primary: Mean Score of Depressive Symptoms — -9.50; -8.30 score on a scale
N/A N=17 Varenicline and Nicotine Interactions in Humans (VA)
Smoking Cessation
Primary: Subjective Responses to Intravenous Nicotine — 23; 38; 51; 14 millimeters — p=<0.05
N/A N=213 Very Low Nicotine Content Cigarettes and E-Cigarettes in Promoting Smoking Cessation in Daily and Intermittent Cigarette Smokers
Cigarette Smoking-Related Carcinoma · Tobacco-Related Carcinoma
Primary: Usual Brand Cigarettes Per Day — 15.803; 2.1563; 1.8353; 1.4931 Cigarettes per Day
N/A N=52 Impact of E-cigarette Nicotine Concentration on Compensation
Smoking Cessation
Primary: Total Inhaled Volume — 416.5; 490.3 mL
N/A N=20 Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study
Cigarette Smoking-Related Carcinoma
Primary: PET/CT Imaging of the Head — 2.81; 2.40 %TAD/kg
Phase 1 N=16 The Interaction of Flavor With Nicotine Form in Adult Smokers
Nicotine Dependence
Primary: Changes in Liking of E-cigarette Overall — 14.2; 5.3; 11.9; 2.2 score on a scale — p=0.01
N/A N=26 Nicotine Flux, a Potentially Powerful Tool for Regulating Nicotine Delivery From Electronic Cigarettes
Nicotine Vaping
Primary: Change in Maximum Arterial Blood Nicotine Delivery (Cmax) — 3.75; 2.48; 8.12; 2.96 ng/ml
Phase 3 N=25 Combination of E-cigarettes and Varenicline for Tobacco Harm Reduction
Smoking Cessation · Harm Reduction
Primary: Number of Participant Reporting Continuous Complete Switching From Cigarettes to Halo G6 — 8 Participants
Phase 2 N=94 The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products
Nicotine Dependence, Cigarettes
Primary: Expired Air Carbon Monoxide (CO) to Assess Recent Smoking — 18.3; 22.9; 21.3; 25.6 Parts per million (ppm) — p=0.01
Phase 2 N=49 Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco
Nicotine Dependence, Cigarettes, Uncomplicated
Primary: Average Cigarettes Smoked Per Day — 4.3; 8.0 average cigarettes per day — p=.111
Phase 2 N=14 Nicotine Vaccination and Nicotinic Receptor Occupancy
Nicotine Dependence
Primary: Mean of the Average Nicotine Binding % at Scan 1 and Scan 2 — 54.9; 49.1 percentage of average nicotine binding — p=<0.05
Phase 3 N=74 Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day
Tobacco Use Disorder
Primary: Feasibility as Indicated by Self-reported Adherence to Study Cigarettes. — 7.1; 7.3; 10.4; 13.3 Percent non-study cigarettes per day
N/A N=35 Low Nicotine Cigarettes, Smoking, and Chronic Pain
Chronic Pain · Smoking, Cigarette
Primary: Cigarettes Smoked Per Day — 14.5; 17.2; 16.4; 20.3 cigarettes/day — p=<.0001
Phase 2 N=46 CAN-DOSE Study: Cessation With Augmented Nicotine for Dual Use Of Smoking and E-cigarettes
Smoking Cessation · Electronic Cigarette Use · Cigarette Smoking
Primary: Days of Dual Use Abstinence — 3.8; 11.2; 6.9; 4.6 Days
Phase 2 N=160 A Study of Cytisinicline for Vaping Cessation in Adult Smokers
Vaping · E-Cig Use
Primary: Percentage of Participants With Vaping Abstinence From Week 9 to 12 — 15.1; 31.8 percentage of participants — p=0.0350
N/A N=24 User Acceptability of a Nicotine Lactate Delivery System (P3L)
Smoking
Primary: Change From Baseline Plasma Concentration of Nicotine/Cotinine After Each ad Libitum Use Session. — 1.7621; 2.4113; 1.9446; 5.5571 (ng/mL)
N/A N=40 The Acute Effect of Vaping on Food Intake
Energy Intake · Food Intake · E-Cig Use
Primary: Energy Intake — 1102.1; 1003.4; 910.4; 868.3 Kilocalories
N/A N=1,132 Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes
Tobacco Use, Cigarette Use
Primary: Very Low Nicotine Content (VLNC) Misperception — 3.12; 3.04; 3.04; 3.36 score on a scale